Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

December 01, 2005 (Vol. 25, No. 21)

Biosimilars Shake up the Biologics Market

Take the Necessary Steps to Prepare or Risk Being Left Behind

  • Loss of patent protection now leads to a rapid decrease in sales for the innovators' branded small molecule drugs in the U.S. and, to a lesser extent, Europe. Exceptions in the U.S. include new branded indications (three years additional exclusivity) and novel delivery systems (exclusivity for life of patent ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.